Puma Biotechnology (PBYI) Surges Over 200% on Statistically Significant Phase III PB272, Amended Licensing Deal with Pfizer
Tweet Send to a Friend
Shares of Puma Biotechnology, Inc. (NYSE: PBYI) are surging 222% in after-hours trade following positive top line results from the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
